Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

被引：24

作者：

Pizzuti, Laura ^{[1
]}

Giordano, Antonio ^{[2
]}

Michelotti, Andrea ^{[3
]}

Mazzotta, Marco ^{[4
]}

Natoli, Clara ^{[5
]}

Gamucci, Teresa ^{[6
,7
]}

De Angelis, Claudia ^{[3
]}

Landucci, Elisabetta ^{[3
]}

Diodati, Lucrezia ^{[3
]}

Iezzi, Laura ^{[5
]}

Mentuccia, Lucia ^{[6
]}

Fabbri, Agnese ^{[8
]}

Barba, Maddalena ^{[1
]}

Sanguineti, Giuseppe ^{[9
]}

Marchetti, Paolo ^{[4
,10
]}

Tomao, Silverio ^{[11
]}

Mariani, Luciano ^{[12
]}

Paris, Ida ^{[13
]}

Lorusso, Vito ^{[14
]}

Vallarelli, Simona ^{[14
]}

Cassano, Alessandra ^{[15
]}

Airoldi, Francesca ^{[15
]}

Orlandi, Armando ^{[15
]}

Moscetti, Luca ^{[16
]}

Sergi, Domenico ^{[1
]}

Sarobba, Maria Giuseppina ^{[17
]}

Tonini, Giuseppe ^{[18
]}

Santini, Daniele ^{[18
]}

Sini, Valentina ^{[19
]}

Veltri, Enzo ^{[20
]}

Vaccaro, Angela ^{[5
]}

Ferrari, Laura ^{[5
]}

De Tursi, Michele ^{[4
]}

Tinari, Nicola ^{[4
]}

Grassadonia, Antonino ^{[4
]}

Greco, Filippo ^{[21
]}

Botticelli, Andrea ^{[2
]}

La Verde, Nicla ^{[22
]}

Zamagni, Claudio ^{[23
]}

Rubino, Daniela ^{[23
]}

Cortesi, Enrico ^{[24
]}

Magri, Valentina ^{[24
]}

Pomati, Giulia ^{[24
]}

Scagnoli, Simone ^{[24
]}

Capomolla, Elisabetta ^{[25
]}

Kayal, Ramy ^{[26
]}

Scinto, Angelo Fedele ^{[27
]}

Corsi, Domenico ^{[27
]}

Cazzaniga, Marina ^{[28
]}

Laudadio, Lucio ^{[29
]}

机构：

[1] IRCCS Regina Elena Natl Canc Inst, Div Med Oncol 2, Via Elio Chianesi 53, I-00144 Rome, Italy

[2] Sapienza Univ Rome, Azienda Osped St Andrea, Dept Clin & Mol Med, Rome, Italy

[3] Azienda Osped Univ Pisana, Dipartimento Oncol Dei Trapianti & Nuove Tecnol, UO Oncol Med I, Osped S Chiara, Pisa, Italy

[4] Ctr Sci Invecchiamento & Med Traslazionale CeSI M, Chieti, Italy

[5] Loc San Marciano Hosp, SS Trinita Hosp, Med Oncol Unit, Sora, Frosinone, Italy

[6] SS Trinita Hosp, Med Oncol Unit, Sora, Italy

[7] Sandro Pertini Hosp, Med Oncol, Rome, Italy

[8] Belcolle Hosp, Med Oncol Unit, Viterbo, Italy

[9] IRCCS Regina Elena Natl Canc Inst, Rome, Italy

[10] Sapienza Univ Rome, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[11] Univ Roma La Sapienza, A Oncol Div, Dept Clin & Mol Med, Rome, Italy

[12] IRCCS Regina Elena Natl Canc Inst, Dept Gynaecol Oncol, HPV Unit, Rome, Italy

[13] Univ Cattolica Sacro Cuore, Gynecol Oncol Unit, Rome, Italy

[14] Giovanni Paolo II Hosp, IRCCS, Div Med Oncol, Bari, Italy

[15] Univ Cattolica Sacro Cuore, Dept Med Oncol, Rome, Italy

[16] Univ Hosp Modena, Dept Hematol & Oncol, Div Med Oncol, Modena, Italy

[17] Osped San Francesco, Div Med Oncol, Nuoro, Italy

[18] Univ Campus Biomed Rome, Dept Oncol, Rome, Italy

[19] Santo Spirito Hosp, Oncol Unit, ASL Roma 1, Rome, Italy

[20] Osped S Maria Goretti, Div Med Oncol, Latina, Italy

[21] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[22] ASST Fatebenefratelli Sacco Fatebenefratelli, Dept Oncol, Milan, Italy

[23] St Orsola Marcello Malpighi Hosp, SSD Oncol Med Addarii, Bologna, Italy

[24] Univ Rome, Policlin Umberto I, Med Oncol, Rome, Italy

[25] Osped Parodi Delfino, Med Oncol, Colleferro, Italy

[26] IRCCS Regina Elena Natl Canc Inst, Dept Radiol, Rome, Italy

[27] Osped San Pietro Fatebenefratelli, Med Oncol Unit, Rome, Italy

[28] ASST Monza, Oncol Unit, Monza, Italy

[29] Osped Renzetti, Med Oncol, Lanciano, Italy

[30] Mater Salutis Hosp, ULSS21, Dept Pathol Surg & Oncol, Verona, Italy

[31] ASST Bergamo Ovest, Oncol Unit, Dept Oncol, Treviglio, Italy

[32] Regina Margherita Hosp, Med Oncol Unit, Rome, Italy

[33] Tor Vergata Univ Hosp, Tor Vergata Clin Ctr, Univ Hosp, Med Oncol Unit,Dept Syst Med, Rome, Italy

[34] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy

[35] Univ Aquila, S Salvatore Hosp, Med Oncol Dept, Laquila, Italy

[36] Univ Politecn Marche, Azienda Osped Univ Ospedali Riuniti Clin Oncol, Ancona, Italy

[37] Univ Cattolica Sacro Cuore, Inst Gen Pathol, Rome, Italy

[38] IRCCS Regina Elena Natl Canc Inst, Biostat Unit, Via Elio Chianesi 53, I-00144 Rome, Italy

[39] IRCCS Regina Elena Natl Canc Inst, Sci Direct, Rome, Italy

来源：

JOURNAL OF CELLULAR PHYSIOLOGY | 2019年 / 234卷 / 06期

关键词：

advanced breast cancer; hormonal therapy; endocrine resistance; palbociclib; real-world setting; 1ST-LINE TREATMENT; FULVESTRANT; COMBINATION; LETROZOLE; EFFICACY; SAFETY; MULTICENTER; ABEMACICLIB; PLACEBO; WOMEN;

D O I：

10.1002/jcp.27832

中图分类号：

Q2 [细胞生物学];

学科分类号：

071009 ; 090102 ;

摘要：

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6-35.4) and clinical benefit was 52.7% (95% CI, 48-57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8-16) and median overall survival was 24 months (95% CI, 17-30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2-, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

引用

页码：7708 / 7717

页数：10

共 50 条

[21] HER2 up-regulation with neoadjuvant endocrine therapy in patients with hormone receptor-positive, HER2-negative breast cancer
Chaudhary, Lubna N.
Jorns, Julie
Gonyo, MaryBeth
Kong, Amanda
Peck, Amy R.
Sun, Yunguang
Bergom, Carmen
Banarjee, Anjishnu
Chitambar, Christopher
Rui, Hallgeir
CANCER RESEARCH, 2020, 80 (04)
[22] Real-world treatment duration of subsequent therapy after palbociclib (PAL) in patients with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in Japan
Sawaki, Masataka
Muramatsu, Yasuaki
Togo, Kanae
Iwata, Hiroji
CANCER RESEARCH, 2023, 83 (05)
[23] Real-world effectiveness and sensitivity of palbociclib plus endocrine therapy in HR+/HER2-patients with metastatic breast cancer
Li, Jingping
Zhang, Xiangmei
Yang, Chao
Lv, Yalei
Yang, Hua
Kong, Xiangshun
Han, Meng
Wang, Zunyi
Ma, Jie
Han, Jianjun
Liu, Yunjiang
MEDICINE, 2021, 100 (44)
[24] Real-World Clinical and Economic Outcomes Associated with Palbociclib for HR-Positive/HER2 Negative Metastatic Breast Cancer: A Commentary
Babcock, Aram
Ali, Askal Ayalew
Balkrishnan, Rajesh
Montero, Alberto
Diaby, Vakaramoko
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (07): : 826 - 831
[25] Real-world effectiveness of palbociclib plus endocrine therapy in HR+/HER2-advanced breast cancer: final results from the POLARIS trial
Tripathy, Debu
Blum, Joanne L.
Karuturi, Meghan S.
Mccune, Steven
Kurian, Sobha
Moezi, Mehdi
Anderson, Daniel
Gauthier, Eric
Zhang, Zhe
Montelongo, Monica Z.
Wang, Yao
Rocque, Gabrielle B.
ONCOLOGIST, 2024,
[26] Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series
Schettini, Francesco
De Santo, Irene
Rea, Carmen G.
Viggiani, Martina
Buono, Giuseppe
De Angelis, Carmine
Cardalesi, Cinzia
Lauria, Rossella
Giuliano, Mario
Forestieri, Valeria
Thomas, Guglielmo
Maione, Pierfrancesco
Limite, Gennaro
Accurso, Antonello
Malorni, Luca
De Placido, Sabino
Arpino, Grazia
MOLECULAR AND CLINICAL ONCOLOGY, 2020, 12 (05) : 456 - 460
[27] Palbociclib in advanced stage hormone receptor-positive breast cancer: real-world data from a Chilean multicentre registry
Walbaum, Benjamin
Reyes, Jose Miguel
Rodriguez, Pablo
Muniz, Sabrina
Medina, Lidia
Ibanez, Carolina
Merino, Tomas
Pinto, Mauricio P.
Bravo, Maria Loreto
Acevedo, Francisco
Bennett, Jose
Sanchez, Cesar
ECANCERMEDICALSCIENCE, 2023, 17
[28] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Morikawa, Aki
Henry, N. Lynn
CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
[29] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
Kovac, Anja
Kuhar, Cvetka Grasic
Ovcaricek, Tanja
Matos, Erika
Mencinger, Marina
Borstnar, Simona
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer
da Silva, Leonardo Roberto
de Andrade, Camila Annicchino
Brenelli, Fabricio
Ramalho, Susana
Reinert, Tomas
de Souza, Alessandra Borba Anton
da Silva, Ana Elisa Ribeiro
de Paula Leite Kraft, Maria Beatriz
de Vasconcelos, Vivian Castro Antunes
Frasson, Antonio Luiz
Torresan, Renato Zochio
Cabello, Cesar
Ellis, Matthew J.
Zeferino, Luiz Carlos
BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 753 - 760

← 1 2 3 4 5 →